$SNY

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.

Nine drugmakers, including Astellas and Sun Pharma, joined Trump's drug-pricing initiative. Novartis paused cell therapy trials but saw success in MS drug trials. CDC excluded two measles deaths from the national tally. Pfizer's Paxlovid showed no benefit in long COVID trial.

U.S. President Trump has secured drug-pricing deals with over 20 pharmaceutical companies, including Pfizer, Johnson & Johnson, and Novo Nordisk, to reduce prescription costs. Agreements involve 'most-favoured-nation' pricing, sales through TrumpRx.gov, and U.S. investment pledges in exchange for tariff relief. Companies like Pfizer and Novo Nordisk have committed to significant price reductions on specific drugs.

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax (via Sanofi and Takeda) for the 2026–2027 season, targeting the XFG variant. The approvals are based on clinical and real-world data, with Pfizer and BioNTech's vaccine set to ship immediately. Over five billion doses of their vaccine have been distributed globally.

The FDA approved updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Sanofi for high-risk adults, including older individuals and those with underlying health conditions. The vaccines target current coronavirus variants and are expected to be available soon. However, federal recommendations on who should receive the shots remain unclear due to legal issues, potentially affecting availability in some states. Medical experts emphasize the vaccines' effectiveness in preventing severe illne

The FDA approved updated COVID-19 vaccines for the 2026-2027 season, targeting circulating SARS-CoV-2 variants. Approved vaccines include Moderna's Spikevax and mNexspike, Pfizer-BioNTech's mRNA vaccine, and Novavax and Sanofi's Nuvaxovid. The vaccines cover high-risk patients aged 6 months through 64 years and everyone aged 65 years or older. Moderna's CEO highlighted the vaccines' role in protecting high-risk individuals.

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.

The FDA approved updated Covid vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi targeting the XFG variant. Pfizer plans immediate shipments, and CVS will administer doses. The shots are approved for high-risk groups, with availability expanding. The CDC has yet to issue recommendations, and insurer coverage remains uncertain. The vaccines are deemed safe and effective, despite potential side effects.